Spots Global Cancer Trial Database for ivosidenib
Every month we try and update this database with for ivosidenib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Phase 2 Study of Ivosidenib in Previously Treated Japanese Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation | NCT06081829 | Cholangiocarcin... Cholangiocarcin... | Ivosidenib | 18 Years - | Servier | |
| Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission | NCT05010772 | Acute Myeloid L... | Decitabine and ... Enasidenib Gilteritinib Ivosidenib Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation | NCT03564821 | IDH1 Mutation M... | Ivosidenib | 18 Years - | Massachusetts General Hospital | |
| Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma | NCT04088188 | Advanced Cholan... Metastatic Chol... Unresectable Ch... | Cisplatin Gemcitabine Ivosidenib Pemigatinib | 18 Years - | Academic and Community Cancer Research United | |
| A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms | NCT04955938 | IDH Mutation IDH1 Mutation IDH2 Gene Mutat... Blood Cancer Myeloproliferat... | Ivosidenib Enasidenib Fedratinib | 18 Years - | University of Chicago | |
| CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | NCT04493164 | Acute Myeloid L... Myelodysplastic... Myeloproliferat... Recurrent Acute... Refractory Acut... | Ivosidenib Liposome-encaps... | 18 Years - | M.D. Anderson Cancer Center | |
| Ivosidenib (TIBSOVO®) Combined With Azacitidine According to Current SmPC | NCT06181734 | Acute Myeloid L... | Ivosidenib | 18 Years - | iOMEDICO AG | |
| Personalized Medicine for Advanced Biliary Cancer Patients | NCT05615818 | Biliary Tract N... | Futibatinib Ivosidenib Zanidatamab Trastuzumab Neratinib Encorafenib Binimetinib Niraparib Cisplatin Gemcitabine | 18 Years - | UNICANCER | |
| Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma | NCT05209074 | Pancreatic Duct... Resectable Panc... | Ivosidenib mFOLFIRINOX | 18 Years - 80 Years | Case Comprehensive Cancer Center | |
| A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms | NCT04955938 | IDH Mutation IDH1 Mutation IDH2 Gene Mutat... Blood Cancer Myeloproliferat... | Ivosidenib Enasidenib Fedratinib | 18 Years - | University of Chicago | |
| CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | NCT04493164 | Acute Myeloid L... Myelodysplastic... Myeloproliferat... Recurrent Acute... Refractory Acut... | Ivosidenib Liposome-encaps... | 18 Years - | M.D. Anderson Cancer Center | |
| Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | NCT04774393 | Acute Myeloid L... Recurrent Acute... Refractory Acut... | Decitabine and ... Enasidenib Ivosidenib Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia | NCT04250051 | Recurrent Acute... Recurrent Myelo... Recurrent Myelo... Refractory Acut... Refractory Myel... | Cytarabine Filgrastim Fludarabine Fludarabine Pho... Ivosidenib | 18 Years - | Northwestern University | |
| Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission | NCT05010772 | Acute Myeloid L... | Decitabine and ... Enasidenib Gilteritinib Ivosidenib Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation | NCT06291987 | Myeloproliferat... | Ivosidenib Ruxolitinib | 18 Years - | University of Chicago | |
| A China Bridging Study of Ivosidenib in r/r AML Subjects With an IDH1 Mutation | NCT04176393 | Relapsed or Ref... | ivosidenib | 18 Years - | CStone Pharmaceuticals | |
| A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site | NCT03498521 | Cancer of Unkno... | Alectinib Vismodegib Ipatasertib Olaparib Erlotinib Bevacizumab Vemurafenib Cobimetinib Trastuzumab Sub... Pertuzumab Atezolizumab Carboplatin Paclitaxel Cisplatin Gemcitabine Entrectinib Ivosidenib Pemigatinib | 18 Years - | Hoffmann-La Roche | |
| Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation | NCT03173248 | Newly Diagnosed... Untreated AML AML Arising Fro... Leukemia, Myelo... | AG-120 Placebo Azacitidine | 18 Years - | Servier | |
| A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms | NCT04955938 | IDH Mutation IDH1 Mutation IDH2 Gene Mutat... Blood Cancer Myeloproliferat... | Ivosidenib Enasidenib Fedratinib | 18 Years - | University of Chicago | |
| Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation | NCT06291987 | Myeloproliferat... | Ivosidenib Ruxolitinib | 18 Years - | University of Chicago | |
| Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission | NCT05010772 | Acute Myeloid L... | Decitabine and ... Enasidenib Gilteritinib Ivosidenib Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma | NCT05921760 | IDH1-mutant Cho... | Ivosidenib Recommended Com... Nivolumab Ipilimumab | 18 Years - | Servier | |
| A Phase 2 Study of Ivosidenib in Previously Treated Japanese Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation | NCT06081829 | Cholangiocarcin... Cholangiocarcin... | Ivosidenib | 18 Years - | Servier | |
| Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies | NCT03471260 | Acute Myeloid L... Hematopoietic a... Myelodysplastic... Myeloproliferat... Recurrent Acute... Refractory Acut... | Azacitidine Ivosidenib Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation | NCT06291987 | Myeloproliferat... | Ivosidenib Ruxolitinib | 18 Years - | University of Chicago | |
| Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation | NCT04655391 | Recurrent Acute... | Bosutinib Monoh... Decitabine Enasidenib Mesy... Gilteritinib Fu... Glasdegib Malea... Ivosidenib Venetoclax | 18 Years - | City of Hope Medical Center | |
| Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen | NCT06127407 | Locally Advance... | Ivosidenib 500m... Placebo | 18 Years - | Servier |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
